2674 related articles for article (PubMed ID: 18268278)
1. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
[TBL] [Abstract][Full Text] [Related]
2. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
[TBL] [Abstract][Full Text] [Related]
3. Biological characterization of CD34+ cells mobilized into peripheral blood.
Lemoli RM; Tafuri A; Fortuna A; Catani L; Rondelli D; Ratta M; Tura S
Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S47-50. PubMed ID: 9989890
[TBL] [Abstract][Full Text] [Related]
4. Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
Cesana C; Regazzi E; Garau D; Caramatti C; Mangoni L; Rizzoli V
Haematologica; 1999 Sep; 84(9):771-8. PubMed ID: 10477448
[TBL] [Abstract][Full Text] [Related]
5. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
6. Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both.
Ho AD; Young D; Maruyama M; Corringham RE; Mason JR; Thompson P; Grenier K; Law P; Terstappen LW; Lane T
Exp Hematol; 1996 Nov; 24(13):1460-8. PubMed ID: 8950228
[TBL] [Abstract][Full Text] [Related]
7. Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets.
Chin-Yee IH; Keeney M; Stewart AK; Belch A; Bence-Buckler I; Couban S; Howson-Jan K; Rubinger M; Stewart D; Sutherland R; Paragamian V; Bhatia M; Foley R
Bone Marrow Transplant; 2002 Dec; 30(12):851-60. PubMed ID: 12476276
[TBL] [Abstract][Full Text] [Related]
8. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor.
Ford CD; Greenwood J; Anderson J; Snow G; Petersen FB
Transfusion; 2006 Feb; 46(2):193-8. PubMed ID: 16441594
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
10. Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts.
Theilgaard-Mönch K; Raaschou-Jensen K; Andersen H; Russell CA; Vindeløv L; Jacobsen N; Dickmeiss E
Bone Marrow Transplant; 1999 Feb; 23(3):243-9. PubMed ID: 10084255
[TBL] [Abstract][Full Text] [Related]
11. Harvesting, characterization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood.
Van Epps DE; Bender J; Lee W; Schilling M; Smith A; Smith S; Unverzagt K; Law P; Burgess J
Blood Cells; 1994; 20(2-3):411-23. PubMed ID: 7538347
[TBL] [Abstract][Full Text] [Related]
12. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
13. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
Haas R; Murea S
Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679
[TBL] [Abstract][Full Text] [Related]
14. Detection and quantification of functionally defined hematopoietic progenitor cells and tissue specific mRNA within the peripheral blood of myeloma patients after administration of granulocyte colony-stimulating factor and erythropoietin.
Grassinger J; Mueller G; Hart C; Nilsson SK; Haylock DN; Andreesen R; Hennemann B
Eur J Haematol; 2008 Jan; 80(1):20-30. PubMed ID: 18028434
[TBL] [Abstract][Full Text] [Related]
15. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.
Shapiro F; Yao TJ; Moskowitz C; Reich L; Wuest DL; Heimfeld S; McNiece IK; Gabrilove J; Nimer S; Moore MA
Clin Cancer Res; 1997 Sep; 3(9):1571-8. PubMed ID: 9815845
[TBL] [Abstract][Full Text] [Related]
16. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
17. The alpha4beta1 and alpha5beta1 integrins mediate engraftment of granulocyte-colony-stimulating factor-mobilized human hematopoietic progenitor cells.
Carstanjen D; Gross A; Kosova N; Fichtner I; Salama A
Transfusion; 2005 Jul; 45(7):1192-200. PubMed ID: 15987366
[TBL] [Abstract][Full Text] [Related]
18. [The effect of matrix metalloproteinase-9 in granulocyte colony stimulation factor-induced stem cell mobilization].
Jin FY; Qiu LG; Li QC; Meng HX; Wang YF; Yu Z; Li Q; Han JL
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(42):2966-70. PubMed ID: 17288807
[TBL] [Abstract][Full Text] [Related]
19. Changes in reticulocyte fractions during peripheral stem cell harvesting: role in monitoring stem cell collection.
Remacha AF; Martino R; Sureda A; Sarda MP; Solá C; Tugues D; Amill B; Garcia J; Oliver A
Bone Marrow Transplant; 1996 Feb; 17(2):163-8. PubMed ID: 8640161
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
